Related coverage linked through entity extraction aliases.
Mar 27, 2026
The FDA has approved Optune Pax, a Tumor Treating Fields device, for use with chemotherapy in locally advanced pancreatic cancer. The approval is based on phase 3 trial data showing improved overall survival and pain progression outcomes. This marks the first new treatment approach for this patient population in approximately 30 years.
Mar 23, 2026
A new four-marker blood test detects pancreatic cancer with 91.9% accuracy across all stages and 87.5% accuracy for early-stage disease. The test combines two newly identified proteins with existing biomarkers and can differentiate cancer from non-cancerous conditions. While promising for pancreatic cancer, most cancers still cannot be reliably diagnosed with blood tests alone.
Mar 18, 2026
Diakonos Oncology's Phase 2 glioblastoma trial of DOC1021 continues after independent safety review found no concerns. The company will present clinical data on the dendritic cell therapy at AACR and AAN conferences in April 2026.
Mar 12, 2026
The global next generation drug conjugates market is projected to grow from $3.9 billion in 2026 to $10.9 billion by 2033 at 15.3% CAGR, while the radionuclide drug conjugate segment is forecast to reach $20.22 billion by 2032 at 9.6% CAGR.
Mar 12, 2026
The FDA is accelerating its review of daraxonrasib, a targeted therapy for pancreatic cancer, under a new pilot program that could reduce approval time from 10-12 months to one to two months.
Mar 11, 2026
AstraZeneca terminated its Phase I/IIa trial of AZD0022 for KRASG12D-mutant cancers, withdrew a planned saruparib ovarian cancer platform study, and completed a real-world non-small cell lung cancer treatment review.
Mar 04, 2026
Can-Fite BioPharma's drug candidate namodenoson met its primary endpoint in a Phase 2a pancreatic cancer trial and demonstrated anti-obesity effects in a peer-reviewed preclinical study published in the International Journal of Obesity.
Mar 04, 2026
A computational histology artificial intelligence platform can predict which of two chemotherapy regimens is more effective for individual pancreatic cancer patients, according to a study published in the Journal of Clinical Oncology.
Mar 02, 2026
AIM ImmunoTech partners with Thermo Fisher to design Phase 3 trial for Ampligen in pancreatic cancer, while Innovent Biologics begins dosing patients in Phase 3 study of IBI354 for HER2-positive breast cancer.
Mar 02, 2026
Oncolytics Biotech launches Phase 2 trial of pelareorep immunotherapy in metastatic colorectal cancer, following Fast Track Designation and promising earlier results showing 27-month median survival.
Feb 28, 2026
Researchers unveil pancreatic-targeted lipid nanoparticles using capsule filtration mechanisms, while a contract research organization expands lipid-based vector development services for organ-selective mRNA delivery.
Feb 27, 2026
Researchers develop ultra-sensitive CAR-T cells targeting CD70 for solid tumors and KRASG12V/HLA-A*02:01-specific CAR-T cells for cancers with KRAS mutations, demonstrating efficacy in preclinical models.
Feb 21, 2026
The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration BTK inhibitor regimen for CLL/SLL and cleared monthly dosing for amivantamab in EGFR-mutated NSCLC. Additional regulatory reviews are underway for PCNSL and breast cancer treatments.
Feb 26, 2026
Researchers developed pancreatic-targeted lipid nanoparticles (AH-LNP) that enable precise mRNA delivery to the pancreas through capsule-filter-mediated accumulation. The platform demonstrated efficacy in genome editing and cancer immunotherapy across multiple animal models including non-human primates.
Feb 25, 2026
Researchers report advances in cancer treatment through three distinct approaches: repurposing a heart medication to target lymphoma enzymes, blocking stress proteins to enhance immunotherapy, and developing antibodies that restore immune system attacks on tumors.
Feb 24, 2026
AIM ImmunoTech outlined key milestones for its Phase 2 DURIPANC trial evaluating Ampligen combined with durvalumab in metastatic pancreatic cancer, with primary endpoint evaluation expected in December 2026.
Feb 18, 2026
Researchers have identified how the MYC protein helps pancreatic cancer evade immune detection, while a separate team discovered methods to permanently switch off cancer genes in leukemia through epigenetic therapy targeting Menin and DOT1L proteins.
Feb 19, 2026
Researchers discovered that lipocalin 2 (LCN2), a protein released by stressed cancer cells, helps lung and pancreatic tumors evade the immune system by manipulating macrophages and blocking T cell infiltration.
Feb 13, 2026
Researchers have developed attenuated Listeria bacteria therapies that boost innate immune cells to fight cancer. Two approaches target colorectal cancer and pediatric leukemia, with FDA clearance expected soon for trials in children.
Feb 17, 2026
A UCLA study found that adding immunotherapy to chemotherapy before surgery is safe for borderline-resectable pancreatic cancer patients, with a subset experiencing complete tumor regression despite no overall survival advantage.
